Table 3.
Age-adjusted and multivariate odds ratios for the association between exposure to professional and self-treated lawn products and canine malignant lymphoma
| Exposure | Professionally applied products | Self-applied products | Professionally or self-applied products | |||
|---|---|---|---|---|---|---|
| Cases: Controls | OR (95% CI)a | Cases: Controls | OR (95% CI)a | Cases: Controls | OR (95% CI)a | |
| Use of any lawn care products | ||||||
| No | 182: 341 | 1.2 (0.9–1.7) | 149: 262 | 1.0 (0.7–1.3) | 94: 173 | 1.1 (0.8–1.6) |
| Yes | 74: 113 | 102: 182 | 162: 273 | |||
| Number of lawn care products used | ||||||
| None | 191: 365 | 1 | 194: 333 | 1 | 137: 242 | 1 |
| 1 | 8: 26 | 0.6 (0.3–1.4) | 23: 77 | 0.5 (0.3–0.8) | 19: 89 | 0.4 (0.2–0.7) |
| 2 | 28: 41 | 1.4 (0.8–2.3) | 27: 41 | 1.2 (0.7–2.0) | 51: 73 | 1.3 (0.8–1.9) |
| ≥3 | 38: 46 | 1.5 (0.9–2.5) | 22: 27 | 1.2 (0.7–2.3) | 59: 74 | 1.3 (0.8–1.9) |
| Ptrend | 0.06 | 0.81 | 0.15 | |||
| Type of lawn care product | ||||||
| Herbicide | ||||||
| No | 204: 395 | 1.4 (1.0–2.1) | 222: 403 | 1.0 (0.7–1.5) | 165: 326 | 1.3 (0.9–1.8) |
| Yes | 62:83 | 44: 75 | 101: 152 | |||
| Pesticide | ||||||
| No | 221: 429 | 1.7 (1.1–2.7) | 226: 420 | 1.2 (0.7–1.8) | 189: 376 | 1.4 (1.1–2.0) |
| Yes | 45: 49 | 40: 58 | 77: 102 | |||
| Insect Growth Regulators | ||||||
| No | 254: 460 | 1.2 (0.6–2.6) | 253: 470 | 2.7 (1.1–6.8) | 244: 453 | 1.6 (0.8–2.9) |
| Yes | 12: 18 | 13: 8 | 22: 25 | |||
| Fungicide | ||||||
| No | 257: 470 | 1.8 (0.7–4.8) | 264: 472 | 0.7 (0.1–3.8) | 255: 464 | 1.4 (0.6–3.2) |
| Yes | 9: 8 | 2: 6 | 11: 14 | |||
| Rodenticide | ||||||
| No | 264: 473 | 0.8 (0.2–4.2) | 265: 474 | 0.3 (0.04–3.1) | 263: 470 | 0.6 (0.2–2.4) |
| Yes | 2: 5 | 1: 4 | 3: 8 | |||
| Fertilizer | ||||||
| No | 197: 372 | 1.2 (0.8–1.7) | 216: 383 | 0.9 (0.6–1.4) | 157: 289 | 1.0 (0.8–1.4) |
| Yes | 69: 106 | 50: 95 | 109: 189 | |||
a
OR, odds ratio from multivariate model; CI, confidence interval. Multivariate relative risks were adjusted for age, reference year, weight, history of cancer, and use of cosequin, chondroitin and prednisone.